Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Wealthstream Advisors Inc.

Wealthstream Advisors Inc. boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 3.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,185 shares of the company’s stock after acquiring an additional 120 shares during the period. Wealthstream Advisors Inc.’s holdings in Novo Nordisk A/S were worth $379,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC grew its position in shares of Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after acquiring an additional 37,346 shares in the last quarter. Private Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 155.1% during the third quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after purchasing an additional 20,188 shares during the period. Channel Wealth LLC lifted its position in shares of Novo Nordisk A/S by 15.6% in the 3rd quarter. Channel Wealth LLC now owns 57,353 shares of the company’s stock worth $6,829,000 after buying an additional 7,756 shares during the last quarter. Buckingham Capital Management Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $3,874,000. Finally, Independence Bank of Kentucky raised its stake in Novo Nordisk A/S by 192.7% during the third quarter. Independence Bank of Kentucky now owns 11,490 shares of the company’s stock worth $1,368,000 after acquiring an additional 7,565 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets cut their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Stock Down 0.1 %

NVO stock opened at $106.93 on Thursday. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $479.83 billion, a price-to-earnings ratio of 34.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.42. The firm’s 50-day moving average is $119.68 and its two-hundred day moving average is $129.92.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.